Your AI-Trained Oncology Knowledge Connection!
Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Juergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients with MET exon 14-mutated advanced non-small cell lung cancer.
Lead investigator Fabrice André, MD, PhD, said findings from the SOLAR-1 trial are the first to show benefit in a genomic subgroup of patients with breast cancer and could open the door for genomic testing in breast cancer.
A combination of an immune checkpoint inhibitor and a VEGF inhibitor, avelumab and axitinib, induced 2-fold higher objective response rates compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma, regardless of their PD-L1 expression. Progression-free survival was also significantly improved over sunitinib, according to findings from the phase III JAVELIN Renal 101 trial presented at the 2018 ESMO Congress.
In results from an analysis of the phase III PALOMA-3 trial, patients with hormone receptor-positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy achieved a clinically meaningful benefit in overall survival from the combination of palbociclib plus fulvestrant.
According to a presentation from the ERA 223 trial atthe 2018 ESMO Congress, no improvements in survival endpoints were seen with the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
The combination of atezolizumab and nab-paclitaxel demonstrated a 2.5-month benefit in progression-free survival over nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer, according to findings of the phase III IMpassion130 trial presented at the 2018 ESMO Congress.
Patients with <em>EGFR</em>-mutant non–small cell lung cancer who had <em>MET</em> amplification and <em>EGFR</em> C797S mutations were most likely to have resistance to first-line treatment with osimertinib (Tagrisso), according to preliminary findings presented at the 2018 ESMO Congress.
Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma.
Triplet therapy for advanced, <em>BRAF</em> V600-mutant melanoma led to objective responses in 73% of a small group of patients enrolled in a phase I trial, according to updated results reported at the 2017 ESMO Annual Congress in Madrid.
H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
A multicenter retrospective analysis presented at the 2017 ESMO Congress found that a newly defined subset of patients treated with anti-PD-1/PD-L1 immunotherapy experienced accelerated tumor growth indicative of hyperprogressive disease (HPD).
Vx-001, a cancer vaccine that employs a new strategy targeting a universal tumor antigen, significantly improved overall survival in patients with advanced or metastatic non–small cell lung cancer who developed an immune response to the vaccine, according to findings presented at the 2017 ESMO Annual Congress in Madrid, Spain.
There was no overall survival improvement seen by expanding surveillance from chest x-ray to follow-up with PET-CT scan after surgery for patients with early-stage non–small cell lung cancer, according to data reported during the 2017 ESMO Congress.
According to findings presented at the 2017 ESMO Congress, nab-paclitaxel monotherapy demonstrated efficacy in patients with pretreated advanced nonsquamous non–small cell lung cancer that is not improved by the addition of CC-486.
In patients with previously treated advanced non-small cell lung cancer, <sup> </sup>superior progression-free survival was induced with continuous treatment with nivolumab until disease progression compared with a 1-year fixed duration treatment.
Median overall survival findings from treatment with pembrolizumab (Keytruda) were significantly longer compared with chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to mature results from the phase III KEYNOTE-045 study.
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.
When abemaciclib was added to a non-steroidal aromatase inhibitor in treatment-naive patients with HER2-negative, HR-positive advanced breast cancer, the combination reduced the risk of progression of disease or death by 46% compared with either anastrozole or letrozole alone, according to findings from the phase III MONARCH 3 trial.
Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses the recent updates presented at the 2017 ESMO Annual Congress regarding avelumab (Bavencio) monotherapy for patients with urothelial carcinoma.
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated greater progression-free survival in patients with untreated metatatic renal cell carcinoma compared with standard sunitinib (Sutent), according to findings presented at the 2017 ESMO Congress held in Madrid, Spain.
Celeste Lebbé, MD, from the Hôpital Saint Louis, in Paris, France, discusses avelumab treatment in chemotherapy-naive patients with distant metastatic Merkel cell carcinoma during the 2017 ESMO Annual Congress.
In findings reported at the 2017 ESMO Annual congress in Madrid, a majority of patients with advanced melanoma responded to the combination of pembrolizumab (Keytruda) and the investigational IDO1 inhibitor epacadostat.
In patients with metastatic triple negative breast cancer, turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears to be feasible, thereby improving sensitivity to immune therapy with nivolumab.
According to a retrospective analysis of a randomized study presented at the 2017 ESMO Congress, a liquid biopsy that measures tumor mutational burden showed promise for predicting benefit in patients with non–small cell lung cancer treated with a checkpoint inhibitor.
For patients with <em>BRAF</em>-mutant advanced melanoma, the BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib demonstrated significant improvements in progression-free survival (PFS) compared with single-agent vemurafenib or encorafenib, according to updated findings from the phase III COLUMBUS trial presented at the 2017 ESMO Congress.
Treatment with the PD-L1 inhibitor durvalumab (Imfinzi) improved median PFS by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III non–small cell lung cancer who had not progressed following chemoradiotherapy, according to phase III results from the PACIFIC trial presented at the 2017 ESMO Congress.
In results from the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with <em>EGFR</em>-mutant non–small cell lung cancer, osimertinib demonstrated a progression-free survival rate of 18.9 months (95% CI, 12.5-21.4), which was significantly improved over standard therapy.
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of melanoma during the 2017 ESMO Annual Congress.
According to findings from the phase III ALUR and ALEX studies announced ahead of the 2017 ESMO Congress,<sup> </sup>Alectinib demonstrated promising efficacy for patients with <em>ALK</em>-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.
